Browse SLC36A2

Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Cytoplasm
Domain PF01490 Transmembrane amino acid transporter protein
Function

Involved in a pH-dependent electrogenic neuronal transport and sequestration of small amino acids. Transports glycine and proline. Inhibited by sarcosine (By similarity).

> Gene Ontology
 
Biological Process GO:0003333 amino acid transmembrane transport
GO:0006818 hydrogen transport
GO:0006820 anion transport
GO:0006865 amino acid transport
GO:0015672 monovalent inorganic cation transport
GO:0015711 organic anion transport
GO:0015804 neutral amino acid transport
GO:0015807 L-amino acid transport
GO:0015808 L-alanine transport
GO:0015816 glycine transport
GO:0015824 proline transport
GO:0015849 organic acid transport
GO:0015992 proton transport
GO:0032328 alanine transport
GO:0035524 proline transmembrane transport
GO:0046942 carboxylic acid transport
GO:1902600 hydrogen ion transmembrane transport
GO:1903825 organic acid transmembrane transport
GO:1905039 carboxylic acid transmembrane transport
Molecular Function GO:0005280 hydrogen:amino acid symporter activity
GO:0005342 organic acid transmembrane transporter activity
GO:0005416 cation:amino acid symporter activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015078 hydrogen ion transmembrane transporter activity
GO:0015171 amino acid transmembrane transporter activity
GO:0015175 neutral amino acid transmembrane transporter activity
GO:0015179 L-amino acid transmembrane transporter activity
GO:0015180 L-alanine transmembrane transporter activity
GO:0015187 glycine transmembrane transporter activity
GO:0015193 L-proline transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015295 solute:proton symporter activity
GO:0022804 active transmembrane transporter activity
GO:0022858 alanine transmembrane transporter activity
GO:0046943 carboxylic acid transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-425374: Amino acid and oligopeptide SLC transporters
R-HSA-352230: Amino acid transport across the plasma membrane
R-HSA-428559: Proton-coupled neutral amino acid transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC36A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC36A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC36A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.3180.042
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8410.454
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.9270.16
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5710.387
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2570.752
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.290.344
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC36A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC36A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC36A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC36A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC36A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC36A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC36A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC36A2
Namesolute carrier family 36 (proton/amino acid symporter), member 2
Aliases PAT2; tramdorin; TRAMD1; tramdorin-1; Solute carrier family 36 member 2; Proton/amino acid transporter 2; Pr ......
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC36A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.